On the same calotropin treatment of cancer cells activates the TGF-β/ERK signaling pathway, by decreasing the expression of TGF-β and ERK1⁄2, and downregulating phosphorylation of ERK1⁄2 (Paesmans et al., 2015). This evidence concerns the gene TGFB1 and cancer.